Choose a language and wait for the translated text.
Shots:
Iovance has reported updated data from Cohorts 1 & 2 of the P-II (IOV-LUN-202) trial evaluating lifileucel in 69 patients with non-squamous mNSCLC that progressed on or after platinum-based CT & ICI therapy
As of Oct 14, 2026, ORR was 24.6% (17/69), consistent with the previously reported 25.6%; ORR was 43.3% in KRAS wild-type vs 11.4% in KRAS-mutant patients, and 59.1% (13/22) in a biomarker-enriched subgroup (KRAS & HER2 wild-type, current or former smokers)
Iovance will begin enrolling the biomarker-enriched POSITILITY cohort in Nov 2026 and plans an sBLA for lifileucel in non-squamous mNSCLC in 2027
Ref: GlobeNewswire | Image: Iovance | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Iovance Reports Updated P-II (IOV-LUN-202) Trial Data of Lifileucel for Non-Squamous Metastatic NSCLC appeared first on PharmaShots.
